The Trifecta — MCAS, POTS, and EDS

The co-occurrence of MCAS, POTS, and Ehlers-Danlos Syndrome (EDS) is so common that it’s informally called “the trifecta.” This isn’t coincidence — there are proposed biological reasons why these three conditions travel together.

EDS: The Structural Foundation

Ehlers-Danlos Syndrome is a group of connective tissue disorders caused by defective collagen or related structural proteins. The most common type, hypermobile EDS (hEDS), features joint hypermobility, tissue fragility, and chronic pain. The genetic basis of hEDS has not been identified (unlike other EDS types where specific collagen gene mutations are known).

Why it connects to mast cells:

Mast Cells are resident cells of connective tissue — they literally live in the collagen matrix. When that matrix is structurally abnormal:

• The mechanical environment changes. Mast cells are mechanosensitive; abnormal tissue stretch and deformation may lower their activation threshold.
• The extracellular matrix (ECM) provides signals that regulate mast cell behavior. Defective ECM may fail to provide normal inhibitory signals or may provide aberrant activating signals.
• Connective tissue laxity leads to increased tissue deformation during normal activity, potentially creating chronic low-grade mechanical activation of local mast cells.

State of evidence

The mechanistic link between EDS and MCAS is still largely hypothetical. The clinical co-occurrence is well-documented and widely recognized by specialists. The molecular explanation — exactly how defective collagen changes mast cell behavior — is an active area of research without definitive answers yet.

POTS: The Autonomic Consequence

POTS (Postural Orthostatic Tachycardia Syndrome) is a form of dysautonomia — the autonomic nervous system doesn’t regulate cardiovascular function properly. On standing, heart rate increases excessively (≥30 bpm or to ≥120 bpm within 10 minutes) without a corresponding drop in blood pressure, or with only a modest drop.

How MCAS drives POTS:

Mast cell mediators directly affect cardiovascular regulation:

• Histamine → vasodilation → blood pools in the lower extremities → reduced venous return → compensatory tachycardia
• Prostaglandins (PGD2) → additional vasodilation
• Heparin release → can affect blood volume regulation
• Chronic mast cell mediator release may damage small autonomic nerve fibers (see Small Fiber Neuropathy), progressively impairing autonomic regulation

How EDS contributes to POTS:

• Hypermobile blood vessels are more compliant (stretchier), allowing more venous pooling
• Lax connective tissue may reduce the effectiveness of the skeletal muscle pump that assists venous return
• Structural abnormalities in the autonomic nervous system’s supporting connective tissue may impair nerve function

How POTS feeds back into MCAS:

• Orthostatic stress activates the sympathetic nervous system → adrenaline and norepinephrine release → these are mast cell triggers (see The HPA Axis and Mast Cells)
• The compensatory tachycardia produces anxiety-like sensations, activating the stress response further
• Poor perfusion from postural changes may stress tissues, lowering mast cell activation thresholds

The Feedback Web

These three conditions don’t just co-occur — they amplify each other:

EDS → abnormal tissue environment → mast cells more easily activated → MCAS MCAS → mediator release → vasodilation, nerve damage → POTS POTS → autonomic stress → sympathetic activation → more mast cell activation → worse MCAS MCAS → chronic inflammation → further connective tissue degradation → worse EDS symptoms

Breaking into this cycle at any point helps, which is why multi-targeted treatment approaches tend to work better than addressing any single condition in isolation.

Why This Constellation Gets Dismissed

The symptoms of the trifecta span nearly every medical specialty:

• Cardiology (tachycardia, blood pressure instability)
• Gastroenterology (GI symptoms from MCAS)
• Dermatology (flushing, hives)
• Rheumatology (joint hypermobility, pain)
• Neurology (brain fog, small fiber neuropathy, dysautonomia)
• Allergy/Immunology (mast cell activation)

No single specialist sees the whole picture. Each sees their piece and may diagnose a fragment: IBS, anxiety, “benign” joint hypermobility, migraine. The unifying pattern — mast cell activation driving multi-system dysfunction in the context of connective tissue disorder and autonomic dysregulation — requires someone who is looking for the pattern.

There is also a significant gender bias. The trifecta disproportionately affects women (or at least is disproportionately diagnosed in women). Multi-system complaints in women are more likely to be attributed to anxiety or somatization. Average time to diagnosis for EDS is 10-20 years. MCAS and POTS often take similarly long.

Where the Research Is Heading

• Genetic studies seeking the molecular basis of hEDS (and its connection to mast cell behavior)
• Characterization of mast cell phenotypes in connective tissue from EDS patients
• Clinical trials of mast cell-targeted therapies for POTS
• Investigation of Small Fiber Neuropathy as a connecting mechanism between all three
• Research into shared autoimmune mechanisms